Table 13 Top 10 pairs of drugs with their correlation with subtype 1 of breast cancer, considering both combined and individually.
From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Drug1 | Drug2 | C. Cor. | Cor. 1 | Cor. 2 | C. Rank | Rank 1 | Rank 2 |
|---|---|---|---|---|---|---|---|
Ruxolitinib | GSK-2636771 | − 0.76 | − 0.59 | − 0.50 | 1 | 1 | 12 |
Tadalafil | PF-04620110 | − 0.70 | − 0.52 | − 0.42 | 2 | 5 | 66 |
Deferiprone | Rimexolone | − 0.69 | − 0.53 | − 0.51 | 3 | 3 | 6 |
Deferiprone | Rupatadine | − 0.69 | − 0.53 | − 0.47 | 4 | 3 | 22 |
Raclopride | Racecadotril | − 0.69 | − 0.47 | − 0.45 | 5 | 24 | 35 |
Tranilast | GSK-2636771 | − 0.68 | − 0.52 | − 0.50 | 6 | 4 | 12 |
Tadalafil | Amikacin | − 0.68 | − 0.52 | − 0.41 | 7 | 5 | 71 |
L-690330 | Favipiravir | − 0.67 | − 0.45 | − 0.44 | 8 | 37 | 44 |
Deferiprone | Etofylline-Clofibrate | − 0.67 | − 0.53 | − 0.48 | 9 | 3 | 16 |
Ruxolitinib | Ribavirin | − 0.67 | − 0.59 | − 0.56 | 10 | 1 | 2 |